Working... Menu

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (PRECYCLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03220178
Recruitment Status : Recruiting
First Posted : July 18, 2017
Last Update Posted : March 25, 2019
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.
Information provided by (Responsible Party):
Palleos Healthcare GmbH

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 31, 2024
  Estimated Study Completion Date : March 31, 2025
Finn RS, Martin M, Rugo HS, Jones SE, Im SA, Gelmon KA, Harbeck N, Lipatov ON, Walshe JM, Moulder SL, Gauthier ER, Lu D, Randolph S, Diéras V, Slamon DJ. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in post-menopausal women with ER+/HER2- advanced breast cancer (ABC). J Clin Oncol 34, 2016 (suppl; abstr 507)
Harbeck, N., R. Wuerstlein and T. Schinkoethe (2015).
Kalbfleisch, J.D., Prentice, R. L. (2002). "The statistical analysis of failure time data" (2nd Ed.) John Wily & Sons, p. 224
Schoenfeld, D. A., Tsiatis, A. A. (1987)."A modified log rank test for highly stratified data." Biometrika, 167-175